Results 131 to 140 of about 527,546 (285)

Identification of Metabolites of the Dietary Supplement Ingredient 5α‐Hydroxy‐Laxogenin

Drug Testing and Analysis, EarlyView.
The biotransformation of the dietary supplement ingredient 5α‐hydroxy‐laxogenin was investigated using human HepG2 cells, the rat and in silico using the online software Next‐gen E‐Resource for Drug Discovery (NERDD). We identified five metabolites generated by the human HepG2 cells of which three and an additional mono‐hydroxylated metabolite were ...
Daniel Derwand, Oliver Zierau, Detlef Thieme, Annekathrin Martina Keiler   +3 more
wiley   +1 more source

Quality-driven programming in global surgery: A 30-Year institutional experience delivering safe, timely and effective surgical care

Annals of Global Health, 2015
L.C. Carlson, K.W. Hatcher, R. Ayala, W.P. Magee, R. Vander Burg   +4 more
doaj   +1 more source

To advance global surgery and anaesthesia, train more advocates

BMJ Global Health, 2023
Robert Riviello, Arsen Muhumuza, Ruben Ayala, Desmond T Jumbam, Abebe Bekele, Atenas Bustamante, Barnabas Tobi Alayande, Jean Cedric Kouam, Irene Dzirasa, Carolina Segura, Fuein Vera Kum, Mikyla Rata, Denis A. Foretia   +12 more
doaj   +1 more source

Weaning from ketogenic diet therapy in children with epilepsy: Insights from a retrospective study

Epilepsia, EarlyView.
Abstract Objective This study was undertaken to describe weaning practices following ketogenic diet therapy (KDT) in children with epilepsy and to identify clinical factors associated with seizure exacerbation or antiseizure medication adjustments during or after weaning from KDT.
Noémie Donnard, Blandine Dozières‐Puyravel, Katia Geraldes, Céline Perrot, Virginie Quéméner, Estelle Goujon, Pierre Truchy, Hala Nasser, François‐Xavier Mauvais, Marion Danse, Stéphane Auvin   +10 more
wiley   +1 more source

Estimating the COP Exchange Rate Volatility Smile and the Market Effect of Central Bank Interventions: A CHARN Approach [PDF]

In this paper we estimated a volatility model for COP/US under two different samples, one containing the information before the “discretional interventions” started, and the other using the whole sample.
Héctor Manuel Zárate, Juan Manuel Julio, Norberto Rodríguez   +2 more
core  

L‐Relationship between uncertainty and average seizure frequency in clinical trials of antiseizure medications

Epilepsia, EarlyView.
Abstract Objective Antiseizure medications are approved based on clinical trials that demonstrate their efficacy as measured by reductions in seizure frequency (SF). When designing these trials, trialists must select inclusion criteria where SF can be reliably measured to maintain statistical power.
Wesley T. Kerr, Neo Kok, Katherine N. McFarlane, Advith S. Reddy, Lavanya Biju, Jacqueline A. French, Daniel M. Goldenholz   +6 more
wiley   +1 more source

FX basket options [PDF]

We explain the valuation and correlation hedging of Foreign Exchange Basket Options in a multi-dimensional Black-Scholes model that allows including the smile.
Hakala, Jürgen, Wystup, Uwe
core  

Memantine treatment in individuals with GRIN gain‐of‐function variants is associated with improvements in behavior, development, and seizure frequency

Epilepsia, EarlyView.
Abstract Objective GRIN‐related disorders due to pathogenic variants in GRIN1, GRIN2A, GRIN2B, or GRIN2D genes are associated with altered N‐methyl‐D‐aspartate receptor (NMDAR) function. Functional changes include gain (GoF) and loss of receptor function (LoF). Clinical reports describing the use of the NMDAR blocker memantine in GRIN‐related disorders
Maike Karnstedt, Riley E. Perszyk, Scott J. Myers, Ellington McDaniels, Marta Somorai, Ingo Borggraefe, Danielle C. M. Veenma, An‐Sofie Schoonjans, Pasquale Striano, Tadeu A. Fantaneanu, Steffen Syrbe, Kristen Park, Wenjuan Chen, Hongjie Yuan, Stephen F. Traynelis, Timothy A. Benke, Johannes R. Lemke, Ilona Krey   +17 more
wiley   +1 more source

Evolution of the European Medicines Agency clinical guidelines for epilepsy drug development between 2010 and 2025: A comparative analysis by the ILAE Task Force on Regulatory Affairs

Epilepsia, EarlyView.
Abstract Objective The latest European Medicines Agency (EMA) guideline on the clinical investigation of medicines to treat epileptic disorders was adopted by the EMA Committee for Medicinal Products for Human Use in 2025. We compared this guideline with the previous version (2010), highlighting areas where significant revisions were introduced ...
Stéphane Auvin, Alexis Arzimanoglou, Jacqueline French, Kelly G. Knupp, Lieven Lagae, Eugen Trinka, Dennis Dlugos, Emilio Perucca   +7 more
wiley   +1 more source

Stiripentol: Unpublished results from the first phase 2 clinical trial in Lennox–Gastaut syndrome conducted in the early 1990s

Epilepsia, EarlyView.
Abstract Objective This study was undertaken to present the results of an exploratory phase 2 trial of stiripentol in Lennox–Gastaut syndrome (LGS). Methods This exploratory single‐blind, single‐arm, nonrandomized sequential‐period phase 2 study was conducted at four centers in France between January 1989 and August 1993.
Stéphane Auvin, Benjamin Serraz, Jérémie Lespinasse, Laurent Chancharme   +3 more
wiley   +1 more source